Shixia Xu, Jiaojiao Yang, Jing Li et al.
preprint
Abstract Background Postpartum depression (PPD) is a common mental disease in postpartum women, which has received more and more attention in society. Ketamine has been confirmed for its rapid antidepressant effect in women with PPD. We speculate that esketamine, an enantiomer of ketamine, pretreatment during cesarean can also reduce the incidence of PPD. Methods All the parturients enrolled in...
Michael Alvear
preprint
Ketamine has emerged as a plausible rapid-acting treatment for post-traumatic stress disorder (PTSD), but the clinical literature is unusually easy to overstate because a small number of randomized trials are repeatedly represented across reviews, several publications reuse the same cohorts, and treatment studies are sometimes mixed with PTSD-prevention studies conducted around acute trauma....
Vivian W. L. Tsang, Brendan Tao, Raimey Olthuis et al.
BACKGROUND Positive feedback from a mental health treatment program that uses treatment adjuncts inspired researchers to assess the potential role of the Apollo Neuro device in mental health outcomes. OBJECTIVE To assess the impact of the Apollo Neuro device on anxiety levels in a ketamine-assisted therapy treatment program, comparing those using the device with those not using the device....
Michael Alvear
preprint
This white paper analyzes aggregate coding results from a six-month review of Reddit discussions concerning oral and sublingual ketamine therapy. The analysis identifies recurring patient-reported themes, including dosing uncertainty, gastrointestinal side effects, bladder and urinary concerns, provider responsiveness, pharmacy variability, cost concerns, treatment tolerance, and integration...
Sophie Holland
This paper explores ketamine as a psychedelic alongside the differential impacts of psychedelic versus psycholytic effects of ketamine in a therapeutic setting. The paper examines existing research to elucidate the broad therapeutic potential of ketamine and the mechanisms underlying each modality. The primary objective is to present the differences between psychedelic and psycholytic...
Anis Murtaza, Reem Altaf, Muzaffar Abbas
preprint
Abstract Schizophrenia (SCZ) is a chronic neuropsychiatric disorder driven by neuroinflammation, microglial overactivation, and pro-inflammatory cytokine dysregulation. Despite antipsychotics, negative and cognitive symptoms remain inadequately treated. This study investigated the therapeutic potential of Chlorogenic Acid (CGA) in a ketamine-induced mouse model of SCZ using integrated in silico...
Zeynep Yoldas, Willys Cantenys, Morgane Tronche et al.
preprint
Background: Facial emotion recognition deficits are well defined in depression but understudied in treatment-resistant depression (TRD). Over the past decades, subanesthetic doses of ketamine have emerged as an effective treatment for TRD, but its effect on affective processing is still little known. Approaches from computational psychiatry, such as sequential evidence sampling models of...
Carlo Sala, Jessica Pagano, Eleonora Mangano et al.
preprint
Abstract Major depressive disorder (MDD) is a leading cause of global disability, and a substantial proportion of patients develop treatment-resistant depression (TRD), highlighting the urgent need for mechanistically novel and fast-acting antidepressants. Ketamine has emerged as a paradigm-shifting therapy due to its rapid and robust antidepressant effects, yet its molecular mechanisms in...
Hannes Schätzle, Frederic von Wegner
Abstract Subanaesthetic ketamine alters the content of consciousness while leaving responsiveness intact. We asked whether this state can be decoded from single eyes-closed EEG epochs, and how spectral power and phase-based connectivity compare when used as features. Re-analysing openly available 62-channel EEG from ten participants (awake versus subanaesthetic ketamine), we trained classifiers...
Vincent Joralemon
preprint
Ketamine’s path from anesthetic to antidepressant reframed treatment-resistant depression (TRD) by shifting focus from monoamines to glutamate/NMDA modulation. This Article traces the science (from Yale–NIMH pilot work through Zarate 2006), synthesizes evidence across routes of administration (IV, IM, oral, sublingual, intranasal) with bioavailability tradeoffs, and explains why esketamine...